Is Biotech in a Bubble? The Bear Case Explained
Biotech IPOs provide some powerful indications...
Why 2014 May Be a Big Year for Opko Health, Inc.
Opko's (OPK) has a number of catalysts this year that could have a big impact on its biggest investor, Philip Frost; including a Tesaro's (TSRO) potential FDA filing for Rolapitant.
3 Stocks to Get on Your Watchlist
SodaStream, Cisco, and Opko Health are this week's must-watch stocks.
Five Prime, Bristol-Myers Squibb Cut $350M Immuno-Oncology Deal
Five Prime, Bristol-Myers Squibb cut $350M immuno-oncology deal.
Should You Believe Tesaro's Hype?
A new license for promising technology from AnaptysBio could eventually help increase the number of drugs in Tesaro's (TSRO) pipeline.
Are We in the Midst of Irrational Exuberance Version 2.0?
It's been 17 years since former Fed chief Alan Greenspan coined the term irrational exuberance, but frothy valuations are once again making the market look top-heavy.
This Week in Biotech: NW Bio Soars While Geron Goes Geronimo
Two early-stage study results, a rare hospital exemption approval in Germany, and a devastating full clinical hold for one biotech are among this week's top biotech stories.